Glaxosmithkline Pharmaceuticals Ltd vs Hindustan Bio Sciences Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 14, 2026

Key Highlights

The Latest Trading Price of Glaxosmithkline Pharmaceuticals Ltd is ₹ 2417 as of 14 May 15:30 . The P/E Ratio of Glaxosmithkline Pharmaceuticals Ltd changed from 68.1 on March 2021 to 52.5 on March 2025 . This represents a CAGR of -5.07% over 5 yearsThe P/E Ratio of Hindustan Bio Sciences Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 24401 crore on March 2021 to ₹ 48743 crore on March 2025 . This represents a CAGR of 14.84% over 5 yearsThe Market Cap of Hindustan Bio Sciences Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Glaxosmithkline Pharmaceuticals Ltd for the Mar '26 is ₹ 1031 crore as compare to the Dec '25 revenue of ₹ 1091 crore. This represent the decline of -5.51% The revenue of Hindustan Bio Sciences Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Glaxosmithkline Pharmaceuticals Ltd for the Mar '26 is ₹ 386.88 crore as compare to the Dec '25 ebitda of ₹ 421.44 crore. This represent the decline of -8.2% The ebitda of Hindustan Bio Sciences Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 182.33 crore to ₹ 277.86 crore over 8 quarters. This represents a CAGR of 23.45% The net profit of Hindustan Bio Sciences Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The Dividend Payout of Glaxosmithkline Pharmaceuticals Ltd changed from 142.13 % on March 2021 to 99.54 % on March 2025 . This represents a CAGR of -6.88% over 5 yearsThe Dividend Payout of Hindustan Bio Sciences Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Glaxosmithkline Pharmaceuticals Ltd

GlaxoSmithKline Pharmaceuticals Limited was erstwhile incorporated as 'Glindia Limited' in November, 1924.
The Company' s name was changed to Glaxo (India) Limited' from Glindia Limited in year 1987 and further to 'GlaxoSmithKline Pharmaceuticals Limited' from Glaxo (India) Limited effective from October 22, 2001. GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma company to unite science, technology and talent to get ahead of disease together.
The Company is headquartered in Mumbai and it has six branch offices, one manufacturing facility at Nashik in Maharashtra, 20 contract manufacturing organisations (CMOs) with regional and sales hubs across India.
The Company is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals.

About Hindustan Bio Sciences Ltd

Hindustan Bio Science Limited was initially incorporated as Garuda Cements Limited in December 1991.
Earlier, it was engaged in cement manufacturing and due to sluggish in the industry, the Company diversified its business into Bio Technology & Pharmaceuticals activities in 2000-01 and the name was changed from Garuda Cements Limited to Hindustan Bio-Sciences Limited.
In 2002, it diversified into software field and subsequently changed its name to Hindustan Bio Sciences Limited on August 8, 2002. The Company engaged in the manufacturing and sale of pharmaceutical products is an integrated firm with diversified businesses in pharmaceutical and biotechnology industries.
The Company initially commenced operations in 1992 by sourcing bulk drugs (APIs) and drug intermediates for the Industry with a wellspring of global suppliers and associates.

FAQs for the comparison of Glaxosmithkline Pharmaceuticals Ltd and Hindustan Bio Sciences Ltd

Which company has a larger market capitalization, Glaxosmithkline Pharmaceuticals Ltd or Hindustan Bio Sciences Ltd?

Market cap of Glaxosmithkline Pharmaceuticals Ltd is 40,958 Cr while Market cap of Hindustan Bio Sciences Ltd is 9 Cr

What are the key factors driving the stock performance of Glaxosmithkline Pharmaceuticals Ltd and Hindustan Bio Sciences Ltd?

The stock performance of Glaxosmithkline Pharmaceuticals Ltd and Hindustan Bio Sciences Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Glaxosmithkline Pharmaceuticals Ltd and Hindustan Bio Sciences Ltd?

As of May 14, 2026, the Glaxosmithkline Pharmaceuticals Ltd stock price is INR ₹2417.75. On the other hand, Hindustan Bio Sciences Ltd stock price is INR ₹9.19.

How do dividend payouts of Glaxosmithkline Pharmaceuticals Ltd and Hindustan Bio Sciences Ltd compare?

To compare the dividend payouts of Glaxosmithkline Pharmaceuticals Ltd and Hindustan Bio Sciences Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.